A study to test how BI 3031185 is tolerated by people with borderline personality disorder or attention-deficit/hyperactivity disorder.
1516-0003
Phase 1 other active
Quick answer
A study to test how BI 3031185 is tolerated by people with borderline personality disorder or attention-deficit/hyperactivity disorder. for Attention deficit hyperactivity disorder, Borderline personality disorder is a Phase 1 program (other) at Boehringer Ingelheim International GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Boehringer Ingelheim International GmbH
- Indication
- Attention deficit hyperactivity disorder, Borderline personality disorder
- Phase
- Phase 1
- Modality
- other
- Status
- active